Gastrin stimulates the growth of
pancreatic cancer cells through the activation of the
cholecystokinin-B receptor (CCK-BR), which has been found to be overexpressed in
pancreatic cancer. In this study, we proposed that the CCK-BR drives growth of
pancreatic cancer; hence, interruption of CCK-BR activity could potentially be an ideal target for
cancer therapeutics. The effect of CCK-BR downregulation in the human pancreatic
adenocarcinoma cells was examined by utilizing specific CCK-BR-targeted RNA interference
reagents. The CCK-BR receptor expression was both transiently and stably downregulated by transfection with selective CCK-BR
small-interfering RNA or
short-hairpin RNA, respectively, and the effects on cell growth and apoptosis were assessed. CCK-BR downregulation resulted in reduced
cancer cell proliferation, decreased
DNA synthesis, and cell cycle arrest as demonstrated by an inhibition of G(1) to S phase progression. Furthermore, CCK-BR downregulation increased
caspase-3 activity, TUNEL-positive cells, and decreased
X-linked inhibitor of apoptosis protein expression, suggesting apoptotic activity.
Pancreatic cancer cell mobility was decreased when the CCK-BR was downregulated, as assessed by a migration assay. These results show the importance of the CCK-BR in regulation of growth and apoptosis in
pancreatic cancer. Strategies to decrease the CCK-BR expression and activity may be beneficial for the development of new methods to improve the treatment for patients with
pancreatic cancer.